Osimertinib Improve...
Clear all

Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations

Joined: 3 years ago
Posts: 531
Topic starter  

"Osimertinib (Tagrisso) improves survival in people with non-small cell lung cancer with EGFR mutations, updated clinical trial results show. People treated with osimertinib lived longer than those treated with earlier-generation EGFR-targeted drugs."


"In the trial, dubbed FLAURA, patients with advanced NSCLC who received osimertinib as an initial treatment lived approximately 7 months longer than patients treated with erlotinib (Tarceva) or gefinitib (Iressa). And the survival improvement did not come at the cost of safety; the investigators saw no increase in serious side effects in people treated with osimertinib." 

Topic Tags